Sorafenib💖

T:👉Bu yani faz 3 çalışması (Lancet yayını*) ameliyat edilemez karaciğer kanserli hastalar için (hepatocellular carcinoma/hcc) camrelizumab ile rivoceranib kombinasyonun sorafenib e kıyasla genel yaşam süresini önemli ölçüde iyileştirdiğini gösterdi (22 aya karşı 15 ay).

Bu…

Hi everyone, i need “Sorafenib” medicine for my uncle urgently, please hmu if you have any leads.

🚨 #LiverCancer Experts
🤯 i hear lots of concerns on #varicealbleeding when using #Antiangiogenesis #Bevacizumab for #HCC treatment
BUT
‼️ dont forget: anti #VEGF & #sorafenib actually decrease #portalpressure
✅PH is common in #cirrhosis , thus, also in HCC
➡️use #betablockers

Check out our new paper on cHCC-CCA:

💁🏻‍♂️Main finding: outcome between CHT- and sorafenib-treated patients not different

Arndt Vogel
Lorenz Balcar
Bernhard Scheiner
ESMO - Eur. Oncology
#LiverTwitter
MedUni Wien

doi.org/10.1016/j.esmo…

Happy to have presented 2 posters in my first in person ASH meeting- looking at “Sorafenib maintenance post Allo HCT in FLT3-ITD AML patients with focus on dosage and FLT3-ITD AF” and “Outcomes of Allo HCT in elderly patients ≥ 70 years old”. #ASH2023

Come join us at HCC-LIVE and attend our Product Theater presentation.

Topic: Impact of liver function on survival outcomes during treatment with camrelizumab + rivoceranib vs sorafenib

Presenter: Arndt Vogel, MD, PhD, Professor of Medicine, University of Toronto, Longo Family…

🔥off the press: Tislelizumab vs Sorafenib as 1st line Treatment for HCC
JAMA Oncology
doi.org/10.1001/jamaon…
👉ORR: 14.3% vs 5.4%
👉mOS: 15.9 vs 14.1mo
🧐non-inferiority, in line with Nivo & Durva, but we need a 'niche' or a biomarker...
ESMO - Eur. Oncology EASL Education ILCA #livertwitter

SABR for HCC
SABR is superior to Sorafenib ( Medan OS = 17m Vs 9.6 m)
Dose 40-50Gy /3-5#
SABR = RFA
1 yr OS = 70-80%
2 yr OS = 40-50%

Largest Metaanalysis
1/2/3 yr OS = 72% / 58% / 48%

1/2/3 yr LC = 86%/83% /83%

Toxicity
GI Gr3 or more= 3.9%
Hepatic Gr3 Or more = 4.7%

FLT(3)-ing about: the search for the best inhibitor.
>>> Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG ashpublications.org/blood/article/… #leusm

could be dissected off. Thanks to team anaesthesia & surgery bharath shiva Does any one else has good response with sorafenib?
Young Oncologists Group India🇮🇳 Dr Gaurav Agarwal Endocrine & Breast Surgeon Suhani Dhaval Patel Julie A Sosa, MD Andrea Merrill, MD FACS Dr Navneet Tripathi 🇮🇳 Barb Miller Latin American Thyroid Society Shivakumar Thiagarajan Dr Parvinder S.Lubana,MS,FACS

Empiezan a notarse los efectos secundarios del Lenvima creo que serán algo mas duros que los del Sorafenib. Al menos encuanto a dolores musculares y articulares.
La sensación de malestar ha vuelto.
Que haré? aguantar, como siempre, esperando a que los biomarcadores sean tan ...

Sorafenib Plus SBRT Improves Survival in Locally Advanced HCC onclive.com/view/sorafenib… via @onclive #GI23

Cabozantinib/atezo vs sorafenib vs Cabo for HCC
The Lancet Gastroenterology & Hepatology
doi.org/10.1016/S2468-…
🔎COSMIC-312 phs-3: final results
👉 mPFS: 6.9 vs 4.3 vs 5.8 mo
👉no OS benefit for IO-combination
👉Consistent efficacy for cabo in 1st & 2nd line HCC
ESMO - Eur. Oncology EASLnews ILCA…

#LiverTwitter sharing our latest article in Liver Cancer (IF12.3) on the changing trends and survival with #Sorafenib in advance #HCC . Median OS with #Sorafenib in the current decade: 13.4 months.

Arndt Vogel Daniel Huang Nicholas Syn 武蔵野赤十字病院 消化器内科 Musashino Red Cross GI Hepatology

🔓 karger.com/Article/Abstra…

#NewsInBrief : Radiation + #Sorafenib Extends Survival for HCC.
bit.ly/3SbRyNZ

NRG/RTOG 1112 positive showing improvement in mOS with SBRT with sorafenib for advanced HCC. Probably not as applicable now with Atezo/Bev but the clearly liver-directed therapy + systemic therapy for HCC is the future.

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study - ScienceDirect sciencedirect.com/science/articl…

#ESMO2023 ESMO - Eur. Oncology wonderful experience to present the outcomes of the Sorafenib stop study in #desmoid in front of the Sarcoma fraternity. I am thankful to AIIMS, New Delhi Medical Oncology Department.

Sorafenib maintenance post SCT for FLT3 pos AML 5 yrs analysis
Better OS 72 vs. 55%
Better LFS 70 vs. 49%
Better GRFS 58 vs. 39%
Lower relapse 15 vs. 36%
No diff in NRM and cGVHD
The Lancet Haematology thelancet.com/journals/lanha…